Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

Mitomycin 3Abiraterone Acetate 3motexafin gadolinium 2abiraterone 2Suspensions 2Sunitinib 2Powders 2Paclitaxel 2Gemcitabine 2Drug Therapy 2Docetaxel 2vinflunine 1valrubicin 1temsirolimus 1sipuleucel-T 1pembrolizumab 1palbociclib 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1gallium 68 PSMA-11 1enfortumab vedotin 1darolutamide 1atezolizumab 1apalutamide 1abemaciclib 1Watchful Waiting 1Transurethral Resection of Prostate 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urogenital Neoplasms × (225)Ac-PSMA-617 × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡